PsychedelicNewsBreaks Archive - Page 50 of 68

FridayMay 14, 2021 9:38 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Six Keys to Leadership Growth in “Forbes” Article

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was featured in a recent “Forbes” article touting six keys to leadership growth. In the article, McKee shared valuable insight into the most effective ways that leaders can grow and develop. The behaviors McKee encouraged include staying curious and stepping outside of your comfort zone as well as not waiting for experiences and making experiences as you go. McKee also urged potential leaders to never stop learning and, in fact, noted that they could learn from every experience. McKee also encouraged leaders to not be afraid of breaking with convention.…

ThursdayMay 13, 2021 11:53 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Collaborates to Potentially Develop New Therapy for Treatment-Resistant Psychiatric Disorders

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently acquired Adelia Therapeutics, thereby adding CYB003 to its pipeline. It subsequently made an equally important move when it inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. According to a recent article, “The agreement, which is scheduled to start this month, calls for the two companies to work together to potentially develop a novel, fast-acting therapy for treatment-resistant psychiatric…

WednesdayMay 12, 2021 11:47 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Opens Functional Mushroom Direct-to-Consumer Store on Amazon

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has opened an online, direct-to-consumer, e-commerce store through its wholly owned subsidiary, Pure Mushrooms Corp. The store, which will sell Pure Mushrooms Reishi and Maitake product formulations, is on the Amazon platform. Pure Mushroom Reishi and Maitake formulations are available in convenient, gluten-free capsules; the company anticipates releasing a Lion’s Man formulation this summer. “We are excited to be on Amazon, the largest online marketplace and the most powerful platform in the world for brand…

TuesdayMay 11, 2021 9:44 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) CEO Talks Business in Two Video Interviews

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) director and CEO Hugh Rogers was a featured guest on two different video interviews. In both interviews, Rogers shared key information and updates about XPhyto, a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. During his InvestorIntel interview with host Peter Clausi, Rogers mentioned that the company had recently received European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system called Covid-ID Lab, which is now registered within the European Union as a commercial in vitro diagnostic (“CE-IVD”) test. During the interview, Rogers noted that the…

MondayMay 10, 2021 1:11 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Integrates Cutting-Edge Tech for Faster Throughput, Highest Quality

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) has ordered a state-of-the-art Cosolvent Injection System (“CIS”) from British Columbia-based Vitalis. The investment will make Pure Extracts one of the first companies in the world to receive the system, which will position it for many benefits. The CIS will be an add-on that enhances Vitalis carbon dioxide extraction systems that Pure Extracts already uses in its facilities. “The CIS provides dramatically faster throughput capacities while maintaining the quality of the cannabis and hemp extracts,” reads a recent article. “Furthermore, the Vitalis CIS has been designed to achieve the optimal ethanol…

MondayMay 10, 2021 10:07 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Master Agreement with Leading CRO Clinlogix

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered into a master service agreement with Clinlogix, a contract research organization (“CRO”). The agreement is a key step for initiating and supporting the clinical development of Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program. Tryp noted that Clinlogix has global experience in providing CRO services for the development of novel pharmaceutical products, and the agreement outlines the collaboration between the two companies, as well as other clinical partners, will include medical writing, biostatistical analysis, data management and trial monitoring. The…

FridayMay 07, 2021 11:03 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Launches ‘Covid-ID Lab’ POC Pilot Project in Germany

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its commencement of a pilot project with its rapid COVID-19 PCR test ("Covid-ID Lab") in a point-of-care ("POC") setting in Germany. Covid-ID Lab was recently approved in Europe and offers the accuracy of a PCR test in only 25 minutes. Validated work flows, including mobile collection and processing of patient samples, will be further optimized during the test. XPhyto's clinical partner for the project is Spitzweg Apotheke, a well-known pharmacy in Langen near Frankfurt, Germany, currently running a COVID-19 test center at a clinic, where it also provides special pharmacy…

FridayMay 07, 2021 9:28 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) CEO to Present at Global Small Cap Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced that CEO Doug Drysdale will be presenting at the upcoming Benzinga Global Small Cap Conference. The conference, slated for Thursday, May 13, 2021, is designed to connect promising small cap companies with investors and traders. Drysdale’s presentation on Cybin is scheduled to begin at 3:55 p.m. ET. The presentation will be broadcast live; a replay will also be available for seven days following the conference. In addition to his Cybin presentation, Drysdale will also serve as a key member of a panel discussion focused on investing…

ThursdayMay 06, 2021 1:00 pm

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured on Gamechangers LIVE

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) was featured in a recent episode of Gamechangers LIVE, a podcast series that shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. XPhyto Therapeutics’ CEO and Director, Hugh Rogers, joined the broadcast, hosted by Executive Coach and Speaker Sergio Tigera, to discuss the company’s various lines of business, including its work to scale industrial production of pharmaceutical-grade psychedelics. “The psychedelic space is really exciting. This is absolutely the cutting edge of mental…

MondayMay 03, 2021 3:21 pm

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Significant Market Opportunity

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, raised eyebrows when it announced that XPhyto Laboratories Inc., its Alberta subsidiary, added mescaline production to its psychedelic medicine development programs earlier this year (https://ibn.fm/cHwJi). Mescaline has begun attracting legislative attention, much like was the case with cannabis, which gained widening legalization as state after state approved varied uses of hemp and cannabis within their political boundaries. Recently, California Senator Scott Wiener introduced a bill that would decriminalize select hallucinogenics, including mescaline, in part due to research from top medical universities indicating that such substances can have significant benefits…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

PsychedelicNewsBreaks